Pharma MNCs: The menace of 100% subsidiaries - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma MNCs: The menace of 100% subsidiaries

Jul 10, 2000

Over the past one year most MNC pharmaceutical companies seem to have gone through a de–rating in valuations. Most of the stocks are quoting at prices almost 60% below their yearly highs.

Company 52 week high CMP % decline
Glaxo 971 430 -55.7%
Hoechst 1,340 472 -64.8%
SmithKline 445 151 -66.1%
Knoll 658 354 -46.2%
Novartis 1,436 914 -36.4%
Pfizer 640 561 -12.3%

While the overall slowdown in pharmaceutical sector and a consequent slowdown in topline growth seems to be the prime reason for the current valuation there is another factor pertaining to MNC companies in general and MNC pharmaceutical companies in particular which seems to have affected the sentiment in these stocks. And that is the presence of 100% subsidiaries of the parent companies operating in India.

Company 100% subsidiary Comments
Glaxo No Can use SmithKline's 100% arm after the merger is consummated
Hoechst No The only MNC pharma co active in introducing new products through the listed co
SmithKline Yes Crocin, Tums, Eno form part of the 100% sub
Knoll Yes Outsources most of its mfg; new class of products likely through 100% sub
Novartis Yes Introduction of nutritional products through the sub
Pfizer Yes Ostensibly for R & D; lifestyle products likely through the 100% sub.

Of the top six pharmaceutical MNCs four companies viz. Pfizer, Novartis, Knoll and SmithKline Pharmaceutical have 100% subsidiaries operating in India. While the ostensible reason seems to be that these companies would conduct research in India, the fact is that these are most likely to be used to introduce new products.

It could also lead to a situation that eventually the listed company is functional only as a trading company. The strategy that could be adopted is  milk existing brands by transferring manufacturing to low-cost third parties and reduce overheads through VRS and the closure of own plants;  transfer profits where feasible through royalties and technical know how fees and  launch drugs through fully-owned subsidiaries.

To be fair to the management’s of these companies it is far more advantageous for the parent to maintain a 100% subsidiary for the simple reason that while the company earns from the Indian market, it need not share its profits with Indian shareholders. Some large MNC's notably Hoechst and Glaxo are introducing more products through the listed subsidiary and exploring possibilities of tie-ups and alliances to leverage their existing distribution strengths and franchise.

However, it is for the government to have a clear–cut policy on this matter. While the government has allowed MNC pharma companies to hike their stake in their existing subsidiaries to 74%, it is still allowing the setting up of 100% companies (Pfizer has been one of the most recent examples.)

What the government needs to do is to make it compulsory for companies to offer 26% of their equity to the Indian public and free up investment norms for pharmaceutical companies rather than give permission for 100% subsidiaries on a case by case (or is it suitcase by suitcase?) basis. Only that could allow Indian investors to participate in the relatively higher profits of top class MNC pharmaceutical companies who introduce their top of the line patented products post 2005.

Equitymaster requests your view! Post a comment on "Pharma MNCs: The menace of 100% subsidiaries". Click here!

  

More Views on News

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Dec 1, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS